Trials / Completed
CompletedNCT01755897
A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 337 (actual)
- Sponsor
- Huazhong University of Science and Technology · Academic / Other
- Sex
- Female
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
We will conduct a trial to determine whether paclitaxel/cisplatin (TP) as an adjuvant chemotherapy after radical surgery improve disease-free survival (DFS) and overall survival (OS), as well as the quality of life (QoL) among early-stage (FIGO stage IB-IIA) cervical cancer patients with risk factors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | radical hysterectomy + pelvic lymph node dissection | |
| DRUG | Paclitaxel | 135-175 mg/m(2) intravenously (IV) on day 1 |
| DRUG | Cisplatin | 75 mg/m(2) IV on day 2 and 3 |
| DRUG | Cisplatin | 35 mg/m(2) IV once a week |
| RADIATION | Pelvic RT | IMRT |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2017-12-01
- Completion
- 2020-12-01
- First posted
- 2012-12-24
- Last updated
- 2023-05-09
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01755897. Inclusion in this directory is not an endorsement.